Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform. This investigational technology has the potential to alter how we use immunotherapy for a number of diseases, including cancer, allergy and infectious diseases.
Looking for a particular Immunomic Therapeutics, Inc. employee's phone or email?
Immunomic Therapeutics, Inc. Questions
The Immunomic Therapeutics, Inc. annual revenue was $5.3 million in 2026.
Dong-Gun Kim is the CEO of Immunomic Therapeutics, Inc..
24 people are employed at Immunomic Therapeutics, Inc..
Immunomic Therapeutics, Inc. is based in Rockville, Maryland.
The NAICS codes for Immunomic Therapeutics, Inc. are [541, 54, 5417].
The SIC codes for Immunomic Therapeutics, Inc. are [28, 283].
Top Immunomic Therapeutics, Inc. Employees
-
Dong-Gun Kim
Chief Executive Officer at Immunomic Therapeutics, Inc.
Rockville, MD, US35+ -
45+
-
23
-
Yoseph Kuh
FP and A Director at Immunomic Therapeutics, Inc.
Rockville, MD, US21 -
14 -
32
-
Melissa Kemp
Communications Manager at Immunomic Therapeutics, Inc.
Washington, DC, US12
Related Companies
